Asabys Partners Integrates Aliath Bioventures in €468M Strategic Consolidation to Build €1B Life Sciences Platform

Madrid and Barcelona-based investment firm Asabys Partners (搜索)搜索该词条 has announced the strategic integration of Aliath Bioventures (搜索)搜索该词条 (formerly known as Alta Life Sciences (搜索)搜索该词条) in partnership with global investment company AltamarCAM Partners (搜索)搜索该词条. The consolidation expands Asabys' assets under management from €300 million to over €400 million, significantly boosting its investment capacity and generating synergies to create value for investors.

The strategic move represents more than a simple acquisition, as Asabys Partners (搜索)搜索该词条 has set its sights on building a life sciences investment platform exceeding €1 billion ($1.1 billion) in assets under management by 2030. The expansion strategy targets critical market gaps spanning tech transfer, company creation, scale-ups, and growth-stage ventures across the healthcare spectrum.

Proven Track Record and Shared Vision

Since its establishment in 2018, Asabys has invested in 18 companies across biopharma, medtech, and digital health sectors while achieving two successful exits. The integration of Aliath Bioventures (搜索)搜索该词条' experienced team and track record aims to significantly accelerate this trajectory by creating synergies that can generate substantial investor value.

Both firms have previously demonstrated their aligned investment philosophy through co-investments in various ventures including Deepull (搜索)搜索该词条, Ona Therapeutics (搜索)搜索该词条, and Inbrain Neuroelectronics (搜索)搜索该词条. This collaboration history underscores their complementary approaches to healthcare innovation.

"Both teams have had a similar investment approach and that's one of the reasons why we decided to integrate them," said Asabys' co-founders and managing directors Clara Campàs and Josep Sanfeliu. "We don't expect huge changes in our investment strategies. Rather, [we'll] have more power and hands to develop projects that we've been exploring for a while, providing us with the availability to cover the full healthcare spectrum and development stage, accompanying companies from inception to growth."

Strategic Fund Management Structure

Under the new arrangement, the Alta Life Sciences (搜索)搜索该词条 Spain I FCR fund will be co-managed by both Asabys and AltamarCAM. Asabys' founding partners, Clara Campàs and Josep Sanfeliu, will join the Fund's Investment Committee, while the Aliath Bioventures (搜索)搜索该词条 team will be fully integrated into Asabys, with Montserrat Vendrell and José María Fernández becoming partners at the firm.

"Asabys will remain the same. Alta Life Sciences (搜索)搜索该词条 Spain I will be co-managed between Asabys and Altamar, with Josep and Clara joining their investment committee," the co-founders clarified.

Addressing Market Challenges

The timing of this integration addresses specific challenges facing the healthcare investment landscape. When discussing the Alta Life Sciences (搜索)搜索该词条 Spain I FCR fund's need for additional time and resources, Campàs and Sanfeliu explained: "While the M&A/IPO markets remain passive or at low levels, the whole healthcare industry is facing delays in their exit plans. Also, Alta invested in highly innovative and promising technologies that usually take longer to develop than incremental solutions."

This market reality underscores the strategic value of combining resources and expertise to support portfolio companies through extended development cycles, particularly for breakthrough technologies that require patient capital and deep sector knowledge.

Collaborative Ecosystem Approach

Rather than viewing the integration as a competitive maneuver, Asabys' leadership emphasizes their collaborative approach to the European life sciences ecosystem. "Given the 'limited' amount of private capital investing in life sciences in Europe, and the large amount of good companies out there, we don't consider other firms to be competitors but rather co-investors or collaborators who are helping us advance the ecosystem by supporting innovation in healthcare," stated Campàs and Sanfeliu.

Josep Ll. Sanfeliu, Co-Founder and Managing Partner at Asabys Partners (搜索)搜索该词条, commented: "The strategic integration of Aliath Bioventures (搜索)搜索该词条 represents a fantastic opportunity to increase our team and capabilities, accelerating our plans to support the full investment spectrum, investing in the best companies from inception to growth."

Clara Campàs added: "With Aliath and AltamarCAM, we share a similar investment outlook, scientific rigor, and a long-term commitment to founders. The addition of the Aliath team brings deep sector expertise, a proven track record, and a shared entrepreneurial mindset that will strengthen our ability to support the next generation of healthcare innovators."

Future Expansion Plans

The combined entity plans to launch new life sciences funds across diverse market segments, with a new fund targeted for early 2026 alongside other strategic healthcare funds. This aggressive expansion strategy positions the merged organization to become one of the largest life science general partners in Southern Europe.

José Luis Molina, Global CEO of AltamarCAM Partners (搜索)搜索该词条, remarked: "Private markets are undergoing a consolidation phase where success depends on building first-class technical teams and scaling them effectively to maximize investment outcomes. From this perspective, we believe this amalgamation is the best possible way to carry out our management activity in this sector and to continue generating value in the portfolio of the Alta Life Sciences (搜索)搜索该词条 Spain I fund, which, while solid, requires additional time and resources to achieve its target return, which remains our main priority."

The combination establishes a leading investment platform in Europe's competitive life sciences sector, with companies in the Alta Life Sciences (搜索)搜索该词条 Spain I FCR fund continuing to perform well and receiving ongoing support from Asabys going forward.